1 advanced heart failure recognizing options john m. herre, md, facc, facp director, advanced heart...
Post on 23-Dec-2015
219 Views
Preview:
TRANSCRIPT
1
ADVANCED HEART FAILURERECOGNIZING OPTIONS
John M. Herre, MD, FACC, FACP
Director, Advanced Heart Failure ProgramSentara Helathcare
Professor of Medicine Eastern Virginia Medical School
PATIENT 1
• Onset heart failure at age 70• Normal coronary arteries• Optimal oral medical management• Resynchronization ICD• Recurrent hospitalizations for heart failure and
VT• EF < 10 %• LVEDD 7.5 cm
2
PATIENT 1• Age 72• Improvement with milrinone
– Creatinine 0.9– Albumin 3.7– INR 1.2– RA 12 (2-5)– PCW 22 (5-12)– RVSWI 832 (>600)
• Recurrence of symptoms off milrinone
3
WHAT DO YOU RECOMMEND
1. Hospice2. Bridge to hospice with milrinone3. Long term home milrinone4. Heart transplant5. Mechanical circulatory support
4
OUTCOMES OF CONTINUOUS HOME MILRINONE THERAPY
Group 1 yr surv Baseline NYHA 6 m NYHA(if alive)
Bridge to TX/VAD 83.3% 3.89 2
Weaning strategy 73.4 3.92 2
Palliative care 11.1 3.76 3
5
Muthsusamy, JHLT 2012, 31:S14
Figure 12
Source: The Journal of Heart and Lung Transplantation 2012; 31:1052-1064 (DOI:10.1016/j.healun.2012.08.002 )
TRANSPLANT SURVIVAL BY AGE
~240 MillionUS Population ≥ 20 years old
6.24 MillionHF = 2.6% of the population
3.12 Million Systolic HF = 50% of HF population
124,800 Adv. Stage C / NYHA IIIB
Advanced Stage C = 3-4%
156,000 Stage D / NYHA IV = 0.5-5%
70,200 Potential candidates for transplant
THE PROBLEM
2000 heart transplants per year2000 heart transplants per year
Courtesy John O’Connell, MD
DURABLE MECHANICAL CIRCULATORY SUPPORT
8
ASSESSING THE BENEFIT
HEARTMATE II RISK SCORE
9
0.0274 x age – 0.723 x albumin + 0.74 x creatinine + 1.136 x INR for centers with > 15 implants per year
1.978 – 2.6751 + 0.66 + 1.3632 = 1.349
Cowger, JACC, 2013
HEARTMATE II RISK SCORE
10
Cowger, JACC, 2013
PATIENT 1
11
PATIENT 2• 72 years old male• Diabetic• CAD• Prior CABG and mitral valve repair• Recurrent hospitalizations for heart failure• 30 lb weight loss• Creatinine 2.9• Albumin 3.0• INR 1.5
12
WHAT DO YOU RECOMMEND
13
1. Hospice
2. Bridge to hospice with milrinone
3. Long term home milrinone
4. Heart transplant
5. Mechanical circulatory support
SURVIVAL IN HEART FAILURE
14
0
0.5
1
1.5
2
2.5
3
No CKD With CKD Age 75-85 Age > 85
1 hosp
2 hosp
3 hosp
4 hosp
3
2.5
2
1.5
1
0.5
0
No CKD CKD Age 75-85 Age > 85
1
2
3
4
HospitalizationsMedian
Survival
(years)
Setoguchi, Am Heart J 2007
PATIENT 2HEARTMATE II RISK SCORE
15
0.0274 x age – 0.723 x albumin + 0.74 x creatinine + 1.136 x INR for centers with > 15 implants per year
1.9728 – 2.169 + 2.146 + 1.704 = 3.6538
HEARTMATE II RISK SCORE
16
Cowger, JACC 2013
17
Profile Description Time to MCS
1 “Crashing and burning” - critical cardiogenic shock. Within hours
2“Progressive decline” – inotrope dependence with continuing
deterioration.Within a few days
3
“Stable but inotrope dependent” - describes clinical stability on mild-
moderate doses of intravenous inotropes. (Patients stable on temporary
circulatory support without inotropes are within this profile).
Within a few weeks
4“Recurrent advanced heart failure” - “recurrent” rather than
“refractory” decompensation.
Within weeks
to months
5“Exertion intolerant” - describes patients who are comfortable at rest
but are exercise intolerant.Variable
6
“Exertion limited” – a patient who is able to do some mild activity but
fatigue results within a few minutes or any meaningful physical
exertion.
Variable
7
“Advanced ” - describes patients who are clinically stable with a
reasonable level of comfortable activity, despite history of previous
decompensation that is not recent.
Not a candidate
for MCS
SURVIVAL TO DISCHARGE
18
70.4
93.5 95.8
0
20
40
60
80
100
% s
urv
ival
Group 1(n=27)
Group 2(n=48)
Group 3 (n=24)
Boyle JHLT 2011
LENGTH OF STAY
19
4441
17
0
10
20
30
40
50
60D
ay
s
Group 1(n=27)
Group 2(n=48)
Group 3(n=24)
Boyle JHLT 2011
RISK FACTORS FOR EARLY DEATHRisk Factor Hazard Ratio P-value
Prior stroke 1.74 0.005
Prior CABG 1.84 <0.0001
INTERMACS 1 2.87 0.0001
INTERMACS 2 1.84 0.01
BiVAD 3.27 <0.0001
Prior valve surgery 1.81 0.0007
20
Kirklin, JHLT 2012, 31:117
OTHER CONSIDERATIONS• Support system• Understand the risks• Understand the lifestyle• Desire to proceed• Ability to interpret and act on alarms• Understand options including palliative care
21
22
PATIENT 3• 30 years old • ODU graduate• Program Development Director for
Muscular Dystrophy Association• Bought a condo • Acquired a small dog
• Progressive cough and dyspnea for 6 weeks
• Couldn’t carry dog up the steps• Diagnosis – bronchitis, reflux• 2 courses of outpatient antibiotics • Sent to ER by PCP for pneumonia
23
1. Bilateral lower lobe air space opacities with effusions, right greater than left. Findings may be related to multifocal pneumonia or aspiration. Recommend radiographic follow-up to clearance.2. Mildly enlarged cardiac silhouette
HOSPITALIST ASSESSMENT
24
Assessment:
Patient Active Hospital Problem List:
*Community Acquired Pneumonia (4/13/2010)
GERD (Gastroesophageal Reflux Disease) (4/13/2010)
Fatigue (4/13/2010)
Anxiety (4/13/2010)
Plan:
Treat for CAP. Prn nebulizer treatments.
Prn xanax for anxiety.
Continue home celexa.
Recommend repeat imaging during her hospital course.
HOSPITAL COURSE• Respiratory arrest at 11 AM on 4/14• Cardiac arrest at 12 noon• Ejection fraction – 5-10% by echo• Persistent shock despite norepinephrine, dobutamine
• Creatinine 1.1• INR 1.58• Albumin 3.1• SGOT 1158• Lactate13.6
25
WHAT DO YOU DO
1. Continue medical management2. Intraaortic balloon pump3. Temporary mechanical circulatory support4. Durable mechanical circulatory support5. Palliative care
26
SHOCK II
27
HOSPITAL COURSE
• Referred to Advanced Heart Failure Team at 2:30 PM• Briefly staibilized with intraaortic balloon pump• Progressive deterioration over next 30 min• To OR at 6:30PM for Acute Mechanical Circulatory
Support• Regained consciousness• End organ function recovered• Heart transplant 5/3/2010
28
Saturday, May 22, 201019 days post transplant
PATIENT 4• 28 years old male • Air Force veteran• 4-6 month history progressive deterioration• 3 week history of nausea, abdominal pain,
vomiting• Admitted to local hospital on 6/26/2012• INR 6.1• Creatinine 2.7• Albumin 1.9
30
31
PATIENT 4• Diagnosis: acute liver failure, acute renal
failure• Vitamin K, FFP• Considered urgent referral for liver
transplant• Cardiopulmonary arrest 6/27• EF 5-10%• Medical management• Transferred to SNGH 6/28/2012 for acute
mechanical circulatory support
32
MANAGEMENT OPTIONS
1. Continue medical management2. Intraaortic balloon pump3. Temporary mechanical circulatory support4. Durable mechanical circulatory support5. Palliative care
33
PATIENT 4• CentriMag temporary support
device• Restoration of circulation• Changout to durable device• Fungal device infection• Recovery of cardiac function• Device explant• Death from multiorgan failure
and heart failure• Family asks if earlier transfer
would have changed outcome
34
WHAT’S THE DIFFERENCE• Same heart• Same age
• Case 4– Late presentation– Later referral– Irreversible end-organ damage
• Where do you draw the line?
35
SUMMARY• Durable mechanical circulatory
– Referral before progressive renal or liver dysfunction– Referral before pressors are required– Referral before cardiac cachexia develops
• Acute, temporary mechanical circulatory support – Early recognition before irreversible end-organ damage– Early referral– Early initiation of mechanical support– Families of young, healthy patients who die are
litiginous
36
WHO HAS THE VAD?
37
top related